EUVIMEDEUVIMED entdecken
Crossref

Active- and Allosteric-Site Cyclic Peptide Inhibitors of Secreted M. tuberculosis Chorismate Mutase

Renier H P van Neer iD, Patricia K Dranchak iD, Mahesh Aitha, Lijun Liu, Emma K Carlson, Isabella E Jacobsen, Kevin Battaile, Yuhong Fang, Dingyin Tao iD, Ganesha Rai iD, Janak Padia, Scott Lovell und 2 weitere

ACS Infectious Diseases · 2025

DOI: 10.1021/acsinfecdis.4c00798 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, 2025. Verfasst von Renier H P van Neer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, U…. Hauptthemen laut MEDLINE: Mycobacterium tuberculosis, Chorismate Mutase, Peptides, Cyclic, Antitubercular Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: NIH HHS, Intramural NIH HHS, National Center for Advancing Translational Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The secreted Chorismate mutase enzyme of Mycobacterium tuberculosis (*MtbCM) is an underexplored potential target for the development of new antitubercular agents that are increasingly needed as antibiotic resistance rises in prevalence. As an enzyme suspected to be involved in virulence and host-pathogen interactions, disruption of its function could circumvent the difficulty of treating tuberculosis-infected granulomas. Drug development, however, is limited by novel ligand discovery. Currently, *MtbCM activity is measured by using a low throughput acid/base-mediated product derivatization absorbance assay. Here, we utilized an RNA-display affinity selection approach enabled by the Random Peptides Integrated Discovery (RaPID) system to screen a vast library of macrocyclic peptides (MCP) for novel *MtbCM ligands. Peptides identified from the RaPID selection, and analogs thereof identified by analyzing the selection population dynamics, produced a new class of *MtbCM inhibiting MCPs. Among these were two noteworthy "chorismides", whose binding modes were elucidated by X-ray crystallography. Both were potent inhibitors of the CM enzyme activity. One was identified as an allosteric binding peptide revealing a novel inhibition approach, while the other is an active-site binding peptide that when conjugated to a fluorescent probe allowed for the development of a series of alternative fluorescence-based ligand-displacement assays that can be utilized for the assessment of potential *MtbCM inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium tuberculosisChorismate MutasePeptides, CyclicAntitubercular AgentsEnzyme InhibitorsBacterial ProteinsAllosteric SiteCatalytic DomainCrystallography, X-Ray

Stichwörter der Autor:innen

Mycobacterium tuberculosisallosteric bindingassay developmentcyclic peptidesisomeraseligand displacement

Substanzen

Chorismate MutasePeptides, CyclicAntitubercular AgentsEnzyme InhibitorsBacterial Proteins

Autor:innen und Institutionen

  • Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland 20850, United States.
  • Department of Chemistry, Graduate School of Science, The University of Tokyo, Tokyo 113-0033, Japan.
  • Protein Structure and X-ray Crystallography Laboratory, Structural Biology Center, University of Kansas, Lawrence, Kansas 66047, United States.
  • New York Structural Biology Center, NSLS-II, Upton, New York 11973, United States.
  • University of Maryland, Rockville, Maryland 20850, United States.
  • Metabolic Medicine Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland 20892, United States.

ORCID-Profile: Renier H P van Neer, Patricia K Dranchak, Dingyin Tao, Ganesha Rai, Hiroaki Suga, James Inglese

Förderung

  • NIH HHS
  • Intramural NIH HHS
  • National Center for Advancing Translational Sciences
  • NIH Office of the Director
  • Japan Society for the Promotion of Science
  • Brookhaven National Laboratory

Zitieren

APA

van Neer, R. H. P., Dranchak, P. K., Aitha, M., Liu, L., Carlson, E. K., Jacobsen, I. E., Battaile, K., Fang, Y., Tao, D., Rai, G., Padia, J., Lovell, S., Suga, H., & Inglese, J. (2025). Active- and Allosteric-Site Cyclic Peptide Inhibitors of Secreted M. tuberculosis Chorismate Mutase. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.4c00798

Vancouver

van Neer RHP, Dranchak PK, Aitha M, Liu L, Carlson EK, Jacobsen IE, et al. Active- and Allosteric-Site Cyclic Peptide Inhibitors of Secreted M. tuberculosis Chorismate Mutase. ACS Infectious Diseases. 2025. doi:10.1021/acsinfecdis.4c00798

BibTeX
@article{vanNeer2025,
  author = {van Neer, Renier H P and Dranchak, Patricia K and Aitha, Mahesh and Liu, Lijun and Carlson, Emma K and Jacobsen, Isabella E and Battaile, Kevin and Fang, Yuhong and Tao, Dingyin and Rai, Ganesha and Padia, Janak and Lovell, Scott and Suga, Hiroaki and Inglese, James},
  title = {Active- and Allosteric-Site Cyclic Peptide Inhibitors of Secreted M. tuberculosis Chorismate Mutase},
  journal = {ACS Infectious Diseases},
  year = {2025},
  doi = {10.1021/acsinfecdis.4c00798}
}
Kostenlos starten →